Evidence & concentration worksheet · Growth Hormone & Performance
Sermorelin 10 mg
evidence.protocol.withhold-unverified.text
Evidence review
evidence.protocol.withhold-unverified.title
evidence.protocol.withhold-unverified.text
How it works
Sermorelin is a 29-amino-acid analogue of the active amino-terminal portion of human growth hormone-releasing hormone. It stimulates a functioning pituitary to release growth hormone rather than replacing growth hormone directly.
The United States previously approved sermorelin acetate as Geref for pediatric growth-hormone deficiency and diagnostic use. The approved product was withdrawn from the market at the applicant’s request in 2009; FDA later recorded that it was not withdrawn for safety or effectiveness reasons.[1][2]
Benefits & side effects
A review of the historical pediatric program reported that sermorelin could provoke growth-hormone release and that limited data showed increased height velocity in some prepubertal children with idiopathic growth-hormone deficiency. It also noted that final adult-height effects were undetermined and that direct comparison with somatropin was lacking.[4]
Those pediatric and diagnostic findings do not demonstrate better sleep, body composition, energy, muscle, recovery, cognition, or longevity in healthy adults. The popular anti-aging use has no comparable controlled outcome evidence.
Calculator
Concentration and measurement calculator
Use this only to check arithmetic from an authoritative product label, registered study protocol, or qualified clinician.
Arithmetic only — not a dose recommendation
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Source concentration
Source-supplied target
References
References
- U.S. FDA — FDA review noting withdrawal of Geref from the U.S. market (2010)
- U.S. FDA — Macrilen medical review discussing Geref withdrawal status (2017)
- U.S. FDA — Geref orphan-drug designation and approval record (2026)
- Paediatric Drugs — Review of sermorelin in pediatric growth-hormone deficiency (1999)
- U.S. FDA — Understanding the risks of compounded drugs (2026)
- U.S. FDA — Sterile compounded drug recall including sermorelin products (2019)
- World Anti-Doping Agency — 2026 prohibited list (2026)
Other vial sizes